Delivery strategies to control inflammatory response: Modulating M1–M2 polarization in tissue engineering applications

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 349-363

  Alvarez, Mario Moisés ^a,b,c,d   Liu, Julie C ^a,b,e   Trujillo de Santiago, Grissel ^a,b,c,d   Cha, Byung Hyun ^a,b,g   Vishwakarma, Ajaykumar ^a,b   Ghaemmaghami, Amir M ^f   Khademhosseini, Ali ^a,b,c,g,h,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^e PURDUE UNIVERSITY   (United States)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g HARVARD UNIVERSITY   (United States)

^h Konkuk University   (South Korea)

ⁱ KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Anti inflammatory; Controlled release; Inflammation; M1 and M2; Macrophages; Tissue engineering

Indexed keywords

MACROPHAGES; NUCLEIC ACIDS; PHYSIOLOGY; TISSUE; TISSUE HOMEOSTASIS;

ANTI-INFLAMMATORIES; CONTROLLED RELEASE; FUTURE RESEARCH DIRECTIONS; INFLAMMATION; INFLAMMATORY RESPONSE; M1 AND M2; REGENERATIVE MEDICINE; TISSUE ENGINEERING APPLICATIONS;

TISSUE ENGINEERING;

ANTIINFLAMMATORY AGENT; BIOMATERIAL; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; NUCLEIC ACID; PEPTIDE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED DRUG RELEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; MACROPHAGE; MACROPHAGE FUNCTION; MONOCYTE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; TISSUE ENGINEERING; TISSUE REGENERATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL POLARITY; CHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE ACTIVATION; PROCEDURES; SECRETION (PROCESS); TISSUE SCAFFOLD;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOCOMPATIBLE MATERIALS; CELL POLARITY; CYTOKINES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84961775048     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.026     Document Type: Article

References (126)

1. [1] Franz, S., Rammelt, S., Scharnweber, D., Simon, J.C., Immune responses to implants — a review of the implications for the design of immunomodulatory biomaterials. Biomaterials 32 (2011), 6692–6709, 10.1016/j.biomaterials.2011.05.078.
2. [2] Webber, M.J., Khan, O.F., Sydlik, S.A., Tang, B.C., Langer, R., A perspective on the clinical translation of scaffolds for tissue engineering. Ann. Biomed. Eng. 43 (2014), 641–656, 10.1007/s10439-014-1104-7.
3. [3] Veiseh, O., Doloff, J.C., Ma, M., Vegas, A.J., Tam, H.H., Bader, A.R., et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater. 14 (2015), 643–651, 10.1038/nmat4290.
4. [4] Ehashi, T., Takemura, T., Hanagata, N., Minowa, T., Kobayashi, H., Ishihara, K., et al. Comprehensive genetic analysis of early host body reactions to the bioactive and bio-inert porous scaffolds. PLoS One, 9, 2014, e85132, 10.1371/journal.pone.0085132.
5. [5] Badylak, S.F., Gilbert, T.W., Immune response to biologic scaffold materials. Semin. Immunol. 20 (2008), 109–116, 10.1016/j.smim.2007.11.003.
6. [6] Mano, J.F., Silva, G.A., Azevedo, H.S., Malafaya, P.B., Sousa, R.A., Silva, S.S., et al. Natural origin biodegradable systems in tissue engineering and regenerative medicine: present status and some moving trends. J. R. Soc. Interface 4 (2007), 999–1030, 10.1098/rsif.2007.0220.
7. [7] Mills, C.D., Lenz, L.L., Ley, K., Macrophages at the fork in the road to health or disease. Front. Immunol., 6, 2015, 59, 10.3389/fimmu.2015.00059.
8. [8] Chávez-Galán, L., Olleros, M.L., Vesin, D., Garcia, I., Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages. Front. Immunol., 6, 2015, 263, 10.3389/fimmu.2015.00263.
9. [9] Hamilton, J.A., Tak, P.P., The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 60 (2009), 1210–1221, 10.1002/art.24505.
10. [10] Lucca, L.E., Hafler, D.A., Sodium-activated macrophages: the salt mine expands. Cell Res. 25 (2015), 885–886, 10.1038/cr.2015.91.
11. [11] Robbe, P., Draijer, C., Borg, T.R., Luinge, M., Timens, W., Wouters, I.M., et al. Distinct macrophage phenotypes in allergic and nonallergic lung inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 308 (2015), L358–L367, 10.1152/ajplung.00341.2014.
12. [12] Pappas, K., Papaioannou, A.I., Kostikas, K., Tzanakis, N., The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma. Cytokine 64 (2013), 613–625, 10.1016/j.cyto.2013.09.010.
13. [13] Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002), 549–555.
14. [14] Mantovani, A., Sica, A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22 (2010), 231–237, 10.1016/j.coi.2010.01.009.
15. [15] Solinas, G., Germano, G., Mantovani, A., Allavena, P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86 (2009), 1065–1073, 10.1189/jlb.0609385.
16. [16] Zarif, J.C., Hernandez, J.R., Sachsenmeier, K.F., Hollingsworth, R.E., Pienta, K.J., Targeting M2-tumor associated macrophages (M2-TAMs) in prostate cancer. Cancer Res., 75, 2015, 2365-2365, 10.1158/1538-7445.AM2015-2365.
17. [17] Nicol, M.Q., Dutia, B.M., The role of macrophages in influenza A virus infection. Futur. Virol. 9 (2014), 847–862, 10.2217/fvl.14.65.
18. [18] Campbell, J.H., Hearps, A.C., Martin, G.E., Williams, K.C., Crowe, S.M., The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 28 (2014), 2175–2187, 10.1097/QAD.0000000000000408.
19. [19] Martinez, F.O., Helming, L., Gordon, S., Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27 (2009), 451–483, 10.1146/annurev.immunol.021908.132532.
20. [20] Epelman, S., Lavine, K.J., Beaudin, A.E., Sojka, D.K., Carrero, J.A., Calderon, B., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40 (2014), 91–104, 10.1016/j.immuni.2013.11.019.
21. [21] Jakubzick, C., Gautier, E.L., Gibbings, S.L., Sojka, D.K., Schlitzer, A., Johnson, T.E., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39 (2013), 599–610, 10.1016/j.immuni.2013.08.007.
22. [22] Jenkins, S.J., Ruckerl, D., Cook, P.C., Jones, L.H., Finkelman, F.D., van Rooijen, N., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332 (2011), 1284–1288, 10.1126/science.1204351.
23. [23] Sieweke, M.H., Allen, J.E., Beyond stem cells: self-renewal of differentiated macrophages. Science, 342, 2013, 1242974, 10.1126/science.1242974.
24. [24] Davies, L.C., Jenkins, S.J., Allen, J.E., Taylor, P.R., Tissue-resident macrophages. Nat. Immunol. 14 (2013), 986–995, 10.1038/ni.2705.
25. [25] Kzhyshkowska, J., Gudima, A., Riabov, V., Dollinger, C., Lavalle, P., Vrana, N.E., Macrophage responses to implants: prospects for personalized medicine. J. Leukoc. Biol. 98 (2015), 953–962, 10.1189/jlb.5VMR0415-166R.
26. [26] Xia, Z., Triffitt, J.T., A review on macrophage responses to biomaterials. Biomed. Mater. 1 (2006), R1–R9, 10.1088/1748-6041/1/1/R01.
27. [27] Xue, J., Schmidt, S.V., Sander, J., Draffehn, A., Krebs, W., Quester, I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40 (2014), 274–288, 10.1016/j.immuni.2014.01.006.
28. [28] Spiller, K.L., Nassiri, S., Witherel, C.E., Anfang, R.R., Ng, J., Nakazawa, K.R., et al. Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials 37 (2015), 194–207, 10.1016/j.biomaterials.2014.10.017.
29. [29] Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20, 10.1016/j.immuni.2014.06.008.
30. [30] De Paoli, F., Staels, B., Chinetti-Gbaguidi, G., Macrophage phenotypes and their modulation in atherosclerosis. Circ. J. 78 (2014), 1775–1781, 10.1253/circj.CJ-14-0621.
31. [31] Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep., 6, 2014, 13, 10.12703/P6-13.
32. [32] McWhorter, F.Y., Wang, T., Nguyen, P., Chung, T., Liu, W.F., Modulation of macrophage phenotype by cell shape. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17253–17258, 10.1073/pnas.1308887110.
33. [33] Bartneck, M., Warzecha, K.T., Tacke, F., Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg. Nutr. 3 (2014), 364–376, 10.3978/j.issn.2304-3881.2014.11.02.
34. [34] Mirza, R.E., Fang, M.M., Ennis, W.J., Koh, T.J., Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes. Diabetes 62 (2013), 2579–2587, 10.2337/db12-1450.
35. [35] Sindrilaru, A., Peters, T., Wieschalka, S., Baican, C., Baican, A., Peter, H., et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121 (2011), 985–997, 10.1172/JCI44490.
36. [36] McNally, A.K., Anderson, J.M., Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am. J. Pathol. 147 (1995), 1487–1499.
37. [37] Wang, N., Liang, H., Zen, K., Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front. Immunol., 5, 2014, 614, 10.3389/fimmu.2014.00614.
38. [38] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969, 10.1038/nri2448.
39. [39] Brenner, D., Blaser, H., Mak, T.W., Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15 (2015), 362–374, 10.1038/nri3834.
40. [40] Horiuchi, T., Mitoma, H., Harashima, S., Tsukamoto, H., Shimoda, T., Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49 (2010), 1215–1228, 10.1093/rheumatology/keq031.
41. [41] Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686, 10.1016/j.it.2004.09.015.
42. [42] Meng, X.-M., Tang, P.M.-K., Li, J., Lan, H.Y., Macrophage phenotype in kidney injury and repair. Kidney Dis. 1 (2015), 138–146, 10.1159/000431214.
43. [43] Ashcroft, G.S., Jeong, M.-J., Ashworth, J.J., Hardman, M., Jin, W., Moutsopoulos, N., et al. Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen. 20 (2012), 38–49, 10.1111/j.1524-475X.2011.00748.x.
44. [44] Taylor, P.C., Feldmann, M., Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5 (2009), 578–582, 10.1038/nrrheum.2009.181.
45. [45] van Schouwenburg, P.A., Rispens, T., Wolbink, G.J., Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9 (2013), 164–172, 10.1038/nrrheum.2013.4.
46. [46] Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J. Am. Med. Assoc. 295 (2006), 2275–2285, 10.1001/jama.295.19.2275.
47. [47] Grainger, D.W., Controlled-release and local delivery of therapeutic antibodies. Expert. Opin. Biol. Ther. 4 (2004), 1029–1044, 10.1517/14712598.4.7.1029.
48. [48] Shamji, M.F., Hwang, P., Bullock, R.W., Adams, S.B., Nettles, D.L., Setton, L.A., Release and activity of anti-TNFα therapeutics from injectable chitosan preparations for local drug delivery. J. Biomed. Mater. Res. B Appl. Biomater. 90 (2009), 319–326, 10.1002/jbm.b.31289.
49. [49] Friedrich, E.E., Sun, L.T., Natesan, S., Zamora, D.O., Christy, R.J., Washburn, N.R., Effects of hyaluronic acid conjugation on anti-TNF-α inhibition of inflammation in burns. J. Biomed. Mater. Res. A 102 (2014), 1527–1536, 10.1002/jbm.a.34829.
50. [50] Foong, K.S., Patel, R., Forbes, A., Day, R.M., Anti-tumor necrosis factor-alpha-loaded microspheres as a prospective novel treatment for Crohn's disease fistulae. Tissue Eng. C Methods 16 (2010), 855–864, 10.1089/ten.TEC.2009.0599.
51. [51] Marquette, S., Peerboom, C., Yates, A., Denis, L., Langer, I., Amighi, K., et al. Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres. Int. J. Pharm. 470 (2014), 41–50, 10.1016/j.ijpharm.2014.04.063.
52. [52] Carrillo-Conde, B.R., Darling, R.J., Seiler, S.J., Ramer-Tait, A.E., Wannemuehler, M.J., Narasimhan, B., Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles. Chem. Eng. Sci. 125 (2015), 98–107, 10.1016/j.ces.2014.08.015.
53. [53] Erdemli, Ö., Özen, S., Keskin, D., Usanmaz, A., Batu, E.D., Atilla, B., et al. In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. J. Biomater. Appl. 29 (2014), 524–542, 10.1177/0885328214535958.
54. [54] Bartok, B., Firestein, G.S., Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233 (2010), 233–255, 10.1111/j.0105-2896.2009.00859.x.
55. [55] Wang, Q., Li, H., Xiao, Y., Li, S., Li, B., Zhao, X., et al. Locally controlled delivery of TNFα antibody from a novel glucose-sensitive scaffold enhances alveolar bone healing in diabetic conditions. J. Control. Release 206 (2015), 232–242, 10.1016/j.jconrel.2015.03.019.
56. [56] Singh, A., Talekar, M., Raikar, A., Amiji, M., Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. J. Control. Release 190 (2014), 515–530, 10.1016/j.jconrel.2014.04.021.
57. [57] Carvalho, V., Castanheira, P., Faria, T.Q., Gonçalves, C., Madureira, P., Faro, C., et al. Biological activity of heterologous murine interleukin-10 and preliminary studies on the use of a dextrin nanogel as a delivery system. Int. J. Pharm. 400 (2010), 234–242, 10.1016/j.ijpharm.2010.08.040.
58. [58] Braat, H., Peppelenbosch, M.P., Hommes, D.W., Interleukin-10-based therapy for inflammatory bowel disease. Expert. Opin. Biol. Ther. 3 (2003), 725–731, 10.1517/14712598.3.5.725.
59. [59] Kumar, V.A., Taylor, N.L., Shi, S., Wickremasinghe, N.C., D'Souza, R.N., Hartgerink, J.D., Self-assembling multidomain peptides tailor biological responses through biphasic release. Biomaterials 52 (2015), 71–78, 10.1016/j.biomaterials.2015.01.079.
60. [60] Gómez-Rodríguez, J., Stijlemans, B., De Muylder, G., Korf, H., Brys, L., Berberof, M., et al. Identification of a parasitic immunomodulatory protein triggering the development of suppressive M1 macrophages during African trypanosomiasis. J. Infect. Dis. 200 (2009), 1849–1860, 10.1086/648374.
61. [61] Ratanavaraporn, J., Furuya, H., Tabata, Y., Local suppression of pro-inflammatory cytokines and the effects in BMP-2-induced bone regeneration. Biomaterials 33 (2012), 304–316, 10.1016/j.biomaterials.2011.09.050.
62. [62] Spiller, K.L., Anfang, R.R., Spiller, K.J., Ng, J., Nakazawa, K.R., Daulton, J.W., et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials 35 (2014), 4477–4488, 10.1016/j.biomaterials.2014.02.012.
63. [63] Roh, J.D., Sawh-Martinez, R., Brennan, M.P., Jay, S.M., Devine, L., Rao, D.A., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 4669–4674, 10.1073/pnas.0911465107.
64. [64] Awojoodu, A.O., Ogle, M.E., Sefcik, L.S., Bowers, D.T., Martin, K., Brayman, K.L., et al. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13785–13790, 10.1073/pnas.1221309110.
65. [65] Das, A., Segar, C.E., Hughley, B.B., Bowers, D.T., Botchwey, E.A., The promotion of mandibular defect healing by the targeting of S1P receptors and the recruitment of alternatively activated macrophages. Biomaterials 34 (2013), 9853–9862, 10.1016/j.biomaterials.2013.08.015.
66. [66] Kim, Y.-H., Furuya, H., Tabata, Y., Enhancement of bone regeneration by dual release of a macrophage recruitment agent and platelet-rich plasma from gelatin hydrogels. Biomaterials 35 (2014), 214–224, 10.1016/j.biomaterials.2013.09.103.
67. [67] Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C.K., Leipner, C., Schultze-Mosgau, S., et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim. Biophys. Acta 1792 (2009), 746–756, 10.1016/j.bbadis.2009.06.004.
68. [68] Vasconcelos, D.P., Costa, M., Amaral, I.F., Barbosa, M.A., Águas, A.P., Barbosa, J.N., Development of an immunomodulatory biomaterial: using resolvin D1 to modulate inflammation. Biomaterials 53 (2015), 566–573, 10.1016/j.biomaterials.2015.02.120.
69. [69] Vasconcelos, D.P., Costa, M., Amaral, I.F., Barbosa, M.A., Águas, A.P., Barbosa, J.N., Modulation of the inflammatory response to chitosan through M2 macrophage polarization using pro-resolution mediators. Biomaterials 37 (2015), 116–123, 10.1016/j.biomaterials.2014.10.035.
70. [70] He, W., McConnell, G.C., Schneider, T.M., Bellamkonda, R.V., A novel anti-inflammatory surface for neural electrodes. Adv. Mater. 19 (2007), 3529–3533, 10.1002/adma.200700943.
71. [71] Benkirane-Jessel, N., Lavalle, P., Meyer, F., Audouin, F., Frisch, B., Schaaf, P., et al. Control of monocyte morphology on and response to model surfaces for implants equipped with anti-inflammatory agent. Adv. Mater. 16 (2004), 1507–1511, 10.1002/adma.200306613.
72. [72] Schultz, P., Vautier, D., Richert, L., Jessel, N., Haikel, Y., Schaaf, P., et al. Polyelectrolyte multilayers functionalized by a synthetic analogue of an anti-inflammatory peptide, α-MSH, for coating a tracheal prosthesis. Biomaterials 26 (2005), 2621–2630, 10.1016/j.biomaterials.2004.06.049.
73. [73] Go, D.P., Palmer, J.A., Gras, S.L., O'Connor, A.J., Coating and release of an anti-inflammatory hormone from PLGA microspheres for tissue engineering. J. Biomed. Mater. Res. A 100 (2012), 507–517, 10.1002/jbm.a.33299.
74. [74] Go, D.P., Palmer, J.A., Mitchell, G.M., Gras, S.L., O'Connor, A.J., Porous PLGA microspheres tailored for dual delivery of biomolecules via layer-by-layer assembly. J. Biomed. Mater. Res. A 103 (2015), 1849–1863, 10.1002/jbm.a.35319.
75. [75] Kamaly, N., Fredman, G., Subramanian, M., Gadde, S., Pesic, A., Cheung, L., et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6506–6511, 10.1073/pnas.1303377110.
76. [76] Fredman, G., Kamaly, N., Spolitu, S., Milton, J., Ghorpade, D., Chiasson, R., et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med., 7, 2015, 275ra20, 10.1126/scitranslmed.aaa1065.
77. [77] Leoni, G., Neumann, P.-A., Kamaly, N., Quiros, M., Nishio, H., Jones, H.R., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J. Clin. Investig. 125 (2015), 1215–1227, 10.1172/JCI76693.
78. [78] Locatelli, I., Sutti, S., Jindal, A., Vacchiano, M., Bozzola, C., Reutelingsperger, C., et al. Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology 60 (2014), 531–544, 10.1002/hep.27141.
79. −/− mice on western type diet. PLoS One, 10, 2015, e0130484, 10.1371/journal.pone.0130484.
80. [80] Zachman, A.L., Crowder, S.W., Ortiz, O., Zienkiewicz, K.J., Bronikowski, C.M., Yu, S.S., et al. Pro-angiogenic and anti-inflammatory regulation by functional peptides loaded in polymeric implants for soft tissue regeneration. Tissue Eng. A 19 (2013), 437–447, 10.1089/ten.TEA.2012.0158.
81. [81] Bury, M.I., Fuller, N.J., Meisner, J.W., Hofer, M.D., Webber, M.J., Chow, L.W., et al. The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers. Biomaterials 35 (2014), 9311–9321, 10.1016/j.biomaterials.2014.07.057.
82. [82] Lin, C.-C., Metters, A.T., Anseth, K.S., Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFα. Biomaterials 30 (2009), 4907–4914, 10.1016/j.biomaterials.2009.05.083.
83. [83] Su, J., Hu, B.-H., Lowe, W.L., Kaufman, D.B., Messersmith, P.B., Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials 31 (2010), 308–314, 10.1016/j.biomaterials.2009.09.045.
84. [84] Ong, S.-M., Biswas, S.K., Wong, S.-C., MicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration. Adv. Drug Deliv. Rev. 88 (2015), 92–107, 10.1016/j.addr.2015.05.013.
85. [85] Wirtz, S., Neurath, M.F., Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther. 10 (2003), 854–860, 10.1038/sj.gt.3302013.
86. [86] Bhavsar, M.D., Amiji, M.M., Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 15 (2008), 1200–1209, 10.1038/gt.2008.67.
87. [87] Kriegel, C., Amiji, M.M., Dual TNF-α/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin. Transl. Gastroenterol., 2, 2011, e2, 10.1038/ctg.2011.1.
88. [88] Boehler, R.M., Kuo, R., Shin, S., Goodman, A.G., Pilecki, M.A., Gower, R.M., et al. Lentivirus delivery of IL-10 to promote and sustain macrophage polarization towards an anti-inflammatory phenotype. Biotechnol. Bioeng. 111 (2014), 1210–1221, 10.1002/bit.25175.
89. [89] Zhang, M., Gao, Y., Caja, K., Zhao, B., Kim, J.A., Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo. PLoS One, 10, 2015, e0118472, 10.1371/journal.pone.0118472.
90. [90] Al-Barwani, F., Donaldson, B., Pelham, S.J., Young, S.L., Ward, V.K., Antigen delivery by virus-like particles for immunotherapeutic vaccination. Ther. Deliv. 5 (2014), 1223–1240, 10.4155/tde.14.74.
91. [91] Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9 (2010), 923–928, 10.1038/nmat2859.
92. [92] Huang, Z., Gan, J., Jia, L., Guo, G., Wang, C., Zang, Y., et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials 48 (2015), 26–36, 10.1016/j.biomaterials.2015.01.013.
93. [93] Lim, H., Noh, J., Kim, Y., Kim, H., Kim, J., Khang, G., et al. Acid-degradable cationic poly(ketal amidoamine) for enhanced RNA interference in vitro and in vivo. Biomacromolecules 14 (2013), 240–247, 10.1021/bm301669e.
94. [94] Jensen, L.B., Griger, J., Naeye, B., Varkouhi, A.K., Raemdonck, K., Schiffelers, R., et al. Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression. Pharm. Res. 29 (2012), 669–682, 10.1007/s11095-011-0589-0.
95. [95] Sheedy, F.J., Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front. Immunol., 6, 2015, 19, 10.3389/fimmu.2015.00019.
96. [96] Bartneck, M., Schulte, V.A., Paul, N.E., Diez, M., Lensen, M.C., Zwadlo-Klarwasser, G., Induction of specific macrophage subtypes by defined micro-patterned structures. Acta Biomater. 6 (2010), 3864–3872, 10.1016/j.actbio.2010.04.025.
97. [97] Waterfield, J.D., Ali, T.A., Nahid, F., Kusano, K., Brunette, D.M., The effect of surface topography on early NFκB signaling in macrophages. J. Biomed. Mater. Res. A 95 (2010), 837–847, 10.1002/jbm.a.32857.
98. [98] Mohiuddin, M., Pan, H.-A., Hung, Y.-C., Huang, G.S., Control of growth and inflammatory response of macrophages and foam cells with nanotopography. Nanoscale Res. Lett., 7, 2012, 394, 10.1186/1556-276X-7-394.
99. [99] Sussman, E.M., Halpin, M.C., Muster, J., Moon, R.T., Ratner, B.D., Porous implants modulate healing and induce shifts in local macrophage polarization in the foreign body reaction. Ann. Biomed. Eng. 42 (2014), 1508–1516, 10.1007/s10439-013-0933-0.
100. [100] Blakney, A.K., Swartzlander, M.D., Bryant, S.J., The effects of substrate stiffness on the in vitro activation of macrophages and in vivo host response to poly(ethylene glycol)-based hydrogels. J. Biomed. Mater. Res. A 100 (2012), 1375–1386, 10.1002/jbm.a.34104.
101. [101] Bartneck, M., Heffels, K.-H., Pan, Y., Bovi, M., Zwadlo-Klarwasser, G., Groll, J., Inducing healing-like human primary macrophage phenotypes by 3D hydrogel coated nanofibres. Biomaterials 33 (2012), 4136–4146, 10.1016/j.biomaterials.2012.02.050.
102. [102] Garg, K., Pullen, N.A., Oskeritzian, C.A., Ryan, J.J., Bowlin, G.L., Macrophage functional polarization (M1/M2) in response to varying fiber and pore dimensions of electrospun scaffolds. Biomaterials 34 (2013), 4439–4451, 10.1016/j.biomaterials.2013.02.065.
103. [103] Rostam, H.M., Singh, S., Vrana, N.E., Alexander, M.R., Ghaemmaghami, A.M., Impact of surface chemistry and topography on the function of antigen presenting cells. Biomater. Sci. 3 (2015), 424–441, 10.1039/c4bm00375f.
104. [104] Lee, S., Choi, J., Shin, S., Im, Y.-M., Song, J., Kang, S.S., et al. Analysis on migration and activation of live macrophages on transparent flat and nanostructured titanium. Acta Biomater. 7 (2011), 2337–2344, 10.1016/j.actbio.2011.01.006.
105. [105] Refai, A.K., Textor, M., Brunette, D.M., Waterfield, J.D., Effect of titanium surface topography on macrophage activation and secretion of proinflammatory cytokines and chemokines. J. Biomed. Mater. Res. A 70 (2004), 194–205, 10.1002/jbm.a.30075.
106. [106] Alfarsi, M.A., Hamlet, S.M., Ivanovski, S., Titanium surface hydrophilicity modulates the human macrophage inflammatory cytokine response. J. Biomed. Mater. Res. A 102 (2014), 60–67, 10.1002/jbm.a.34666.
107. [107] Barth, K.A., Waterfield, J.D., Brunette, D.M., The effect of surface roughness on RAW 264.7 macrophage phenotype. J. Biomed. Mater. Res. A 101 (2013), 2679–2688, 10.1002/jbm.a.34562.
108. [108] McWhorter, F.Y., Davis, C.T., Liu, W.F., Physical and mechanical regulation of macrophage phenotype and function. Cell. Mol. Life Sci. 72 (2015), 1303–1316, 10.1007/s00018-014-1796-8.
109. [109] Ballotta, V., Driessen-Mol, A., Bouten, C.V.C., Baaijens, F.P.T., Strain-dependent modulation of macrophage polarization within scaffolds. Biomaterials 35 (2014), 4919–4928, 10.1016/j.biomaterials.2014.03.002.
110. [110] Saino, E., Focarete, M.L., Gualandi, C., Emanuele, E., Cornaglia, A.I., Imbriani, M., et al. Effect of electrospun fiber diameter and alignment on macrophage activation and secretion of proinflammatory cytokines and chemokines. Biomacromolecules 12 (2011), 1900–1911, 10.1021/bm200248h.
111. [111] Kitajewski, J., Wnts heal by restraining angiogenesis. Blood 121 (2013), 2381–2382, 10.1182/blood-2013-01-479063.
112. [112] Willenborg, S., Lucas, T., van Loo, G., Knipper, J.A., Krieg, T., Haase, I., et al. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood 120 (2012), 613–625, 10.1182/blood-2012-01-403386.
113. [113] Troidl, C., Jung, G., Troidl, K., Hoffmann, J., Mollmann, H., Nef, H., et al. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr. Vasc. Pharmacol. 11 (2013), 5–12, 10.2174/1570161111309010005.
114. [114] Sainson, R.C.A., Johnston, D.A., Chu, H.C., Holderfield, M.T., Nakatsu, M.N., Crampton, S.P., et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111 (2008), 4997–5007, 10.1182/blood-2007-08-108597.
115. [115] Fantin, A., Vieira, J.M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116 (2010), 829–840, 10.1182/blood-2009-12-257832.
116. [116] Apte, R.S., Richter, J., Herndon, J., Ferguson, T.A., Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med., 3, 2006, e310, 10.1371/journal.pmed.0030310.
117. [117] Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Mills, S.A., Fang, S., Parsa, A.T., Complement and the central nervous system: emerging roles in development, protection and regeneration. Immunol. Cell Biol. 88 (2010), 781–786, 10.1038/icb.2010.48.
118. [118] Stefater, J.A., Rao, S., Bezold, K., Aplin, A.C., Nicosia, R.F., Pollard, J.W., et al. Macrophage Wnt-calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. Blood 121 (2013), 2574–2578, 10.1182/blood-2012-06-434621.
119. [119] Mountziaris, P.M., Mikos, A.G., Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng. B Rev. 14 (2008), 179–186, 10.1089/ten.teb.2008.0038.
120. [120] Yuan, F., Thiele, G.M., Wang, D., Nanomedicine development for autoimmune diseases. Drug Dev. Res. 72 (2011), 703–716, 10.1002/ddr.20479.
121. [121] Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 (2011), 98–107, 10.1038/nri2925.
122. [122] Maurice, D.H., Ke, H., Ahmad, F., Wang, Y., Chung, J., Manganiello, V.C., Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 13 (2014), 290–314, 10.1038/nrd4228.
123. [123] Schett, G., Elewaut, D., McInnes, I.B., Dayer, J.-M., Neurath, M.F., How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19 (2013), 822–824, 10.1038/nm.3260.
124. [124] Tang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332 (2011), 478–484, 10.1126/science.1199214.
125. [125] He, M.M., Smith, A.S., Oslob, J.D., Flanagan, W.M., Braisted, A.C., Whitty, A., et al. Small-molecule inhibition of TNF-alpha. Science 310 (2005), 1022–1025, 10.1126/science.1116304.
126. [126] Epelman, S., Lavine, K.J., Randolph, G.J., Origin and functions of tissue macrophages. Immunity 41 (2014), 21–35, 10.1016/j.immuni.2014.06.013.